<DOC>
	<DOCNO>NCT00729339</DOCNO>
	<brief_summary>Gastroesophageal reflux disease ( GERD ) common disease Western World . In Taiwan , disease increase gradually investigator ' eat style closing Western world . Proton pump main drug patient GERD past two decade . Prokinetic agent important adjuvant therapy GERD . This study aim evaluate role prokinetic agent management GERD .</brief_summary>
	<brief_title>Role Mosapride Patients With Gastroesophageal Reflux Disease</brief_title>
	<detailed_description>This randomize , double-blind , cross-over study . FSSG obtain begin , one month two month study . This study plan enroll 100 patient symptoms GERD ( acid regurgitation , belching , dysphagia ) . After receive endoscopic examination , frequent scale symptom gastroesophageal reflux disease ( FSSG ) obtain patient . Fifty patient receive lansoprazole 30 mg plus mosapride 5 mg tid daily first month ; lansoprazole 30 mg plus placebo tid daily second month . Another fifty patient receive lansoprazole 30 mg plus placebo tid daily first month ; lansoprazole 30 mg plus mosapride 5 mg tid daily second month .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Mosapride</mesh_term>
	<criteria>Aged 18 90 year old Outpatients Characteristic GERD symptom : acid regurgitation , heart burn , belch Erosive esophagitis upper digestive endoscopy , base Los Angeles classification History allergy lansoprazole mosapride Pregnant lactate woman Uremia Decompensated liver disease Age 18 90 yearsold Lack inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Gastroesophageal reflux disease</keyword>
	<keyword>Mosapride</keyword>
	<keyword>Lansoprazole</keyword>
</DOC>